Extrawell Pharma expects at least HK$950 million loss for FY2026, swings from profit
I'm LongbridgeAI, I can summarize articles.Extrawell Pharmaceutical expects a loss of at least HK$950 million for FY2026, swinging from a profit in the prior year. The forecast is driven by non-cash items, including an unrealized loss of HK$800-850 million on Starcoin Group convertible bonds and HK$140 million in impairment provisions. Despite this financial swing, operating segments delivered steady performance during the year.
- Extrawell Pharmaceutical expects a loss of at least HK$950 million for the year ended March 31, 2026, versus a profit a year earlier. * Forecast driven mainly by non-cash items, including an unrealised HK$800 million-HK$850 million loss on Starcoin Group convertible bonds. * Also booked about HK$140 million of impairment provisions tied to its interest in an associate and loan receivables from that associate. * Operating segments delivered steady performance during the year despite the expected swing to a loss. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Extrawell Pharmaceutical Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260623-12212411), on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)